BiomeDx presents first meta-analysis for predicting immune checkpoint inhibitor therapy response.
VIENNA, October 11th, 2021: At the 45th annual conference of the Austrian Society for Pneumology (https://www.ogp-kongress.at/) the team of BiomeDx presents for the first time the meta-analysis on the specificity of microbiome-based signatures for predicting immune checkpoint inhibitor therapy response in non-small cell lung cancer patients. The data presented support current research approaches and suggest that a specific ICI response gut microbiome signature could be applicable across different cancer types.
The data presented virtually this year at the OEGP annual congress supports the potential of our efforts to find a cancer agnostic ICI-response biomarker.Christian Jansen from BiomeDx
BiomeOne® describe the current efforts of BiomeDx® towards the world’s first stool-based response prediction test for immunotherapy (ICI). Currently, the biomarker is tested in three tumor types: non-small-cell lung cancer, renal cell carcinoma and malignant melanoma. Early research efforts support the idea of a tumor agnostic biomarker, that can be used for any tumor type. Read more on BiomeOne®.
Biome Diagnostics GmbH (BiomeDx®) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.
Presented poster: Meta-analysis on the specificity of microbiome-based signatures for predicting immune checkpoint inhibitor therapy response in non-small cell lung cancer patients
Follow us at: https://www.linkedin.com/company/biomediagnostics/